{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040954","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.216917+00:00","generated_at":"2026-06-11T18:39:10.567289+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TScan Q2 net loss $24M, cash $208.8M; heme and solid tumor trials advancing","bullets":["Net loss of $24.0M in Q2 2023, vs $15.1M in Q2 2022; revenue $3.1M (down from $4.1M).","Ended Q2 2023 with cash $208.8M; raising $134.7M net from June public offering; funded into 2026.","FDA cleared IND for TSC-200-A0201 (HPV16); third solid tumor IND; three TCR-Ts to enter Phase 1 basket study H2 2023.","Heme malignancies: TSC-100/101 at dose level 2, no DLTs; expect RP2D and interim data by end of 2023.","Plans to file INDs for three more TCR-Ts by year-end, including PRAME-targeting TSC-203-A0201."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040954","json":"https://secwatch.observer/filing/0000950170-23-040954.json","markdown":"https://secwatch.observer/filing/0000950170-23-040954.md","text":"https://secwatch.observer/filing/0000950170-23-040954.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000095017023040954/0000950170-23-040954-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000095017023040954/tcrx-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:39:10.567289+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"37d92f6f846356862823ffdf69f499a16698d23b","claim":"TScan Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 10, 2023, TScan Therapeutics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017023040954/0000950170-23-040954-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}